Literature DB >> 28013435

Evaluation of quality indicators and disease damage in childhood-onset systemic lupus erythematosus patients.

Julia G Harris1,2, Kristyn I Maletta3, Evelyn M Kuhn3, Judyann C Olson4.   

Abstract

The aim of this study was to describe compliance with select quality indicators and assess organ-specific dysfunction in a childhood-onset systemic lupus erythematosus population by using a validated damage index and to evaluate associations between compliance with quality indicators and disease damage. A retrospective chart review was performed on patients diagnosed with systemic lupus erythematosus prior to age 18 followed at a single center in the USA from 1999 to 2012 (n = 75). Data regarding quality indicators and outcome variables, including the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index, were collected. The median disease duration was 3.8 years. The proportion of patients or patient-years in which care complied with the proposed quality measures was 94.4% for hydroxychloroquine use, 84.3% for vitamin D recommendation,75.8% for influenza vaccination (patient-years), 67.2% for meningococcal vaccination, 49.0% for ophthalmologic examination (patient-years), 31.7% for pneumococcal vaccination, and 28.6% for bone mineral density evaluation. Disease damage was present in 41.3% of patients at last follow-up, with an average damage index score of 0.81. Disease damage at last follow-up was associated with minority race/ethnicity (p = 0.008), bone mineral density evaluation (p = 0.035), and vitamin D recommendation (p = 0.018). Adherence to quality indicators in a childhood-onset systemic lupus erythematosus population is varied, and disease damage is prevalent. This study highlights the importance of quality improvement initiatives aimed at optimizing care delivery to reduce disease damage in pediatric lupus patients.

Entities:  

Keywords:  Disease damage; Outcomes; Quality indicators; Systemic lupus erythematosus

Mesh:

Substances:

Year:  2016        PMID: 28013435     DOI: 10.1007/s10067-016-3518-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  39 in total

1.  Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus.

Authors:  M Bandeira; S Buratti; M Bartoli; C Gasparini; L Breda; A Pistorio; S Grassi; M G Alpigiani; G Barbano; L L Janz-Junior; A Martini; A Ravelli
Journal:  Lupus       Date:  2006       Impact factor: 2.911

2.  Clinical report—bone densitometry in children and adolescents.

Authors:  Laura K Bachrach; Irene N Sills
Journal:  Pediatrics       Date:  2010-12-27       Impact factor: 7.124

3.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

4.  Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage.

Authors:  Hermine I Brunner; Earl D Silverman; Theresa To; Claire Bombardier; Brian M Feldman
Journal:  Arthritis Rheum       Date:  2002-02

5.  Disease activity, severity, and damage in the UK Juvenile-Onset Systemic Lupus Erythematosus Cohort.

Authors:  Louise Watson; Valentina Leone; Clarissa Pilkington; Kjell Tullus; Satyapal Rangaraj; Janet E McDonagh; Janet Gardner-Medwin; Nick Wilkinson; Phil Riley; Jane Tizard; Kate Armon; Manish D Sinha; Yiannis Ioannou; Neil Archer; Kathryn Bailey; Joyce Davidson; Eileen M Baildam; Gavin Cleary; Liza J McCann; Michael W Beresford
Journal:  Arthritis Rheum       Date:  2012-07

6.  Measuring quality in arthritis care: methods for developing the Arthritis Foundation's quality indicator set.

Authors:  Catherine H MacLean; Kenneth G Saag; Daniel H Solomon; Sally C Morton; Sarah Sampsel; John H Klippel
Journal:  Arthritis Rheum       Date:  2004-04-15

Review 7.  The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus.

Authors:  D Gladman; E Ginzler; C Goldsmith; P Fortin; M Liang; M Urowitz; P Bacon; S Bombardieri; J Hanly; E Hay; D Isenberg; J Jones; K Kalunian; P Maddison; O Nived; M Petri; M Richter; J Sanchez-Guerrero; M Snaith; G Sturfelt; D Symmons; A Zoma
Journal:  Arthritis Rheum       Date:  1996-03

8.  Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus.

Authors:  Aimee O Hersh; Emily von Scheven; Jinoos Yazdany; Pantelis Panopalis; Laura Trupin; Laura Julian; Patricia Katz; Lindsey A Criswell; Edward Yelin
Journal:  Arthritis Rheum       Date:  2009-01-15

9.  A quality indicator set for systemic lupus erythematosus.

Authors:  Jinoos Yazdany; Pantelis Panopalis; Joann Zell Gillis; Gabriela Schmajuk; Catherine H MacLean; David Wofsy; Edward Yelin
Journal:  Arthritis Rheum       Date:  2009-03-15

10.  EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics.

Authors:  G Bertsias; J P A Ioannidis; J Boletis; S Bombardieri; R Cervera; C Dostal; J Font; I M Gilboe; F Houssiau; T Huizinga; D Isenberg; C G M Kallenberg; M Khamashta; J C Piette; M Schneider; J Smolen; G Sturfelt; A Tincani; R van Vollenhoven; C Gordon; D T Boumpas
Journal:  Ann Rheum Dis       Date:  2007-05-15       Impact factor: 19.103

View more
  6 in total

1.  Associations between quality of health care and clinical outcomes in patients with rheumatic and musculoskeletal diseases: a rehabilitation cohort study.

Authors:  Anne-Lene Sand-Svartrud; Gunnhild Berdal; Maryam Azimi; Ingvild Bø; Turid Nygaard Dager; Siv Grødal Eppeland; Guro Ohldieck Fredheim; Anne Sirnes Hagland; Åse Klokkeide; Anita Dyb Linge; Joseph Sexton; Kjetil Tennebø; Helene Lindtvedt Valaas; Kristin Mjøsund; Hanne Dagfinrud; Ingvild Kjeken
Journal:  BMC Musculoskelet Disord       Date:  2022-04-15       Impact factor: 2.562

2.  Non-pharmacologic therapies in treatment of childhood-onset systemic lupus erythematosus: A systematic review.

Authors:  Elizabeth Ross; Khalid Abulaban; Elizabeth Kessler; Natoshia Cunningham
Journal:  Lupus       Date:  2022-04-20       Impact factor: 2.858

Review 3.  Use of Quality Measures to Identify Disparities in Health Care for Systemic Lupus Erythematosus.

Authors:  Shilpa Arora; Jinoos Yazdany
Journal:  Rheum Dis Clin North Am       Date:  2020-09-09       Impact factor: 2.670

4.  Comparing the importance of quality measurement themes in juvenile idiopathic inflammatory myositis between patients and families and healthcare professionals.

Authors:  Heather O Tory; Ruy Carrasco; Thomas Griffin; Adam M Huber; Philip Kahn; Angela Byun Robinson; David Zurakowski; Susan Kim
Journal:  Pediatr Rheumatol Online J       Date:  2018-04-19       Impact factor: 3.054

5.  Feasibility and acceptability of an innovative adherence intervention for young adults with childhood-onset systemic Lupus Erythematosus.

Authors:  Onengiya Harry; Lori E Crosby; Constance Mara; Tracy V Ting; Jennifer L Huggins; Avani C Modi
Journal:  Pediatr Rheumatol Online J       Date:  2020-04-26       Impact factor: 3.054

6.  An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus.

Authors:  Vitor Cavalcanti Trindade; Magda Carneiro-Sampaio; Eloisa Bonfa; Clovis Artur Silva
Journal:  Paediatr Drugs       Date:  2021-07-10       Impact factor: 3.022

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.